Radiation therapy for vulvar cancer: consensus guidelines of the GINECOR working group of the Spanish Society of Radiation Oncology. Part 1: clinical recommendations

Sofia Cordoba Largo,Isabel Rodriguez Rodriguez,Silvia Rodriguez Villalba,Dina Najjari Jamal,Javier Anchuelo Latorre,Francisco Celada Álvarez,Sonia Garcia Cabezas,Cristina de la Fuente Alonso,Luz Couselo Paniagua,Irene Martínez Montesinos,Elena Villafranca Iturre,Belén Belinchón Olmeda,Dolores Farga Albiol,Paola Andrea Navarrete Solano,María Sánchez Belda,

DOI: https://doi.org/10.1007/s12094-023-03095-8

2023-03-24

Abstract:PurposeThe present consensus statement was developed by the GINECOR working group on behalf of the Spanish Society of Radiation Oncology (SEOR). Given the lack of prospective data on the management of vulvar carcinoma, this document provides an up-to-date review of radiotherapy treatment in vulvar cancer and a series of consensus-based recommendations from a group of experts.MethodsA two-round, online modified Delphi study was conducted to reach consensus treatment recommendations in three clinical settings: 1) adjuvant treatment, 2) locally-advanced vulvar cancer (LAVC), and 3) recurrent disease. After the first round, we comprehensively reviewed the available medical literature from peer-reviewed journals to assess and define the evidence-based treatment options. In the second round, participants were asked to indicate their level of agreement with the preliminary recommendations according to the GRADE (Grade of Recommendation, Assessment, Development, and Evaluation) criteria, as follows: strongly agree; agree; neither agree nor disagree; disagree; strongly disagree.ResultsThe main recommendations were as follows: 1) following surgical resection, adjuvant radiotherapy is recommended with the presence of adverse risk factors (primarily positive margins and lymph node involvement); 2) radiotherapy (with or without chemotherapy) should be considered in LAVC; and 3) in recurrent disease, radiotherapy should be individualised on a case-by-case basis. A high level of agreement over 80% was reached.ConclusionsIn the absence of robust clinical data, these final recommendations may help to select the optimal radiotherapy approach for this relatively rare cancer.

oncology